首页> 美国卫生研究院文献>Clinical Molecular Pathology >The immunohistochemical expression of calcitonin receptor-like receptor (CRLR) in human gliomas
【2h】

The immunohistochemical expression of calcitonin receptor-like receptor (CRLR) in human gliomas

机译:降钙素受体样受体(CRLR)在人脑胶质瘤中的免疫组织化学表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Gliomas are the most common primary tumours of the central nervous system and exhibit rapid growth that is associated with neovascularisation. Adrenomedullin is an important tumour survival factor in human carcinogenesis. It has growth promoting effects on gliomas, and blockade of its actions has been experimentally shown to reduce the growth of glioma tissues and cell lines. There is some evidence that the calcitonin receptor-like receptor (CRLR) mediates the tumorigenic actions of adrenomedullin.>Aim: To determine whether CRLR is expressed in human gliomas and the probable cellular targets of adrenomedullin.>Methods: Biopsies from 95 human gliomas of varying grade were processed for immunohistochemical analysis using a previously developed and characterised antibody to CRLR.>Results: All tumour specimens were positive for CRLR. As previously found in normal peripheral tissues, CRLR immunostaining was particularly intense in the endothelial cells. This was evident in all the various vascular conformations that were observed, and which are typical of gliomas. In addition, clear immunostaining of tumour cells with astrocyte morphology was observed. These were preferentially localised around vessels.>Conclusions: This study has shown for the first time that the CRLR protein is present in human glioma tissue. The expression of the receptor in endothelial cells and in astrocytic tumour cells is consistent with the evidence that its endogenous ligand, adrenomedullin, may influence glioma growth by means of both direct mitogenic and indirect angiogenic effects. CRLR may be a valuable target for effective therapeutic intervention in these malignant tumours.
机译:>背景:神经胶质瘤是中枢神经系统最常见的原发性肿瘤,并表现出与新血管形成有关的快速生长。肾上腺髓质素是人类癌发生中重要的肿瘤存活因子。它对神经胶质瘤具有促进生长的作用,其作用的阻断已通过实验证明可减少神经胶质瘤组织和细胞系的生长。有证据表明降钙素样受体(CRLR)介导肾上腺髓质素的致瘤作用。>目的:确定CRLR是否在人脑胶质瘤中表达以及肾上腺髓质素的可能细胞靶标。>方法:使用先前开发的特征性CRLR抗体对来自95个不同等级的人脑胶质瘤的活检进行免疫组织化学分析。>结果:所有肿瘤标本均为CRLR阳性。如先前在正常外周组织中发现的那样,CRLR免疫染色在内皮细胞中特别强烈。这在观察到的所有胶质瘤典型的各种血管构象中均很明显。另外,观察到具有星形胶质细胞形态的肿瘤细胞的清晰免疫染色。这些优先定位在血管周围。>结论:这项研究首次表明CRLR蛋白存在于人类神经胶质瘤组织中。该受体在内皮细胞和星形细胞肿瘤细胞中的表达与以下证据相符:该受体的内源性配体肾上腺髓质素可通过直接促有丝分裂和间接血管生成作用来影响神经胶质瘤的生长。 CRLR可能是有效治疗这些恶性肿瘤的重要靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号